Werewolf Therapeutics shareholders elect three Class III directors, ratify EY auditor

Werewolf Therapeutics, Inc.

Elected Michael Atkins, Luke Evnin, and Alon Lazarus as Class III directors; Atkins 31.6M votes for, Evnin 20.7M, Lazarus 31.5M.
Broker non-votes of 5.1M shares on each director election.
Ratified Ernst & Young as independent auditor for FY2024: 36.7M for, 41.9K against, 2.9K abstain.

item 5.07

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-148114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.